Vaccines

The biopharma firm beats 2025 guidance on strong specialty and generic sales, forecasting another year of growth fueled by new product launches.

Neurizon Therapeutics has started dosing its promising ALS drug, NUZ-001, in the groundbreaking HEALEY Platform Trial, a pivotal step for patients.

With the hire of Greg Crescenzi, the famed academic repository signals a major strategic expansion to bridge the gap between scientific sharing and drug development.

Spectral Medical shifts its FDA submission for a breakthrough sepsis device, a strategic move that could strengthen its case but delays a potential lifeline.

With record SUBLOCADE revenue and a new U.S. home, Indivior launches a $400M buyback, signaling a new era in its fight against the opioid crisis.

With soaring sales for its rare obesity drug IMCIVREE, Rhythm Pharmaceuticals faces a critical March FDA decision that could unlock a massive new market.

New analyses of Upstream Bio's verekitug aim to prove its true effectiveness for nasal polyps, setting the stage for a competitive showdown.

A new collaboration is betting on tiny natural particles to deliver a gene-editing cure for a devastating neurological disorder, bypassing a key medical hurdle.

A novel mouse model with human immune receptors promises to slash the high failure rate of antibody therapies, accelerating life-saving treatments.

With its strategic pivot to high-growth Med Tech paying off, all eyes are on AngioDynamics' CEO presentation at the upcoming Leerink healthcare conference.

The biopharma company shatters records with 51% growth in its key drug, ASCENIV, and outlines a strategic overhaul aimed at long-term market dominance.

With a massive late-stage pipeline and deep pockets, the biotech aims to defeat elusive cancer targets, but soaring costs raise the stakes for pivotal trials.

Eton Pharmaceuticals wins landmark FDA approval for DESMODA, a breakthrough liquid drug set to transform care for a rare condition by enabling precise, safe dosing.

A new oral drug shows remarkable success in healing stubborn herpes lesions in people with HIV, offering a much-needed breakthrough for a vulnerable population.

Curanex Pharmaceuticals hits a key manufacturing milestone for Phyto-N, a botanical drug with a 30-year history, advancing its quest for FDA approval.

New subgroup data from ITM's COMPETE trial could refine treatment for a tough-to-treat cancer and bolster the company's position in the radiopharma market.

As Evolus presents at a key healthcare conference, investors watch to see if its new filler line and digital strategy can deliver on bold promises.

As Aura presents its precision oncology pipeline at key conferences, investors will weigh the promise of its lead drug against a challenging financial landscape.

New research reveals how stomach cancer cells hijack healthy tissue to build supportive 'nests' in distant organs, opening a new front in the war on metastasis.

Promising trial data for onvansertib offers new hope for colorectal cancer patients, yet leadership changes and financial hurdles cloud the path forward.